Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.52 |
| ▸ | DDR2 | Q16832 | 2/20 | 0.50 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.49 |
| ▸ | KDR | P35968 | 6/20 | 0.46 |
| ▸ | BRAF | P15056 | 2/20 | 0.46 |
| ▸ | MET | P08581 | 2/20 | 0.45 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.45 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
| ▸ | AXL | P30530 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15574399 | 0.92 | DDR2 (0.61) | EPHX2DDR2P2RX3KDRBRAF | |
| SCHEMBL16990668 | 0.86 | DDR2 (0.60) | DDR2P2RX3KMT2AROCK2 | |
| SCHEMBL16990626 | 0.86 | DDR2 (0.60) | DDR2P2RX3KMT2AROCK2 | |
| SCHEMBL171280 | 0.83 | DDR2 (0.71) | EPHX2DDR2KDRBRAFMET | |
| SCHEMBL15574409 | 0.81 | LMNA (0.57) | KDRBRAFAXL | |
| SCHEMBL16990616 | 0.81 | DDR2 (0.70) | DDR2P2RX3KDRBRAFMEN1 | |
| SCHEMBL16990589 | 0.80 | DDR2 (0.51) | EPHX2DDR2P2RX3KDRBRAF | |
| SCHEMBL16990607 | 0.80 | MEN1 (0.53) | EPHX2DDR2P2RX3KDRBRAF | |
| SCHEMBL16990647 | 0.79 | RAB9A (0.52) | EPHX2DDR2P2RX3KDRBRAF | |
| SCHEMBL16990682 | 0.79 | RAF1 (0.58) | EPHX2DDR2P2RX3KDRBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150225369-A1 | DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | MERCK PATENT GMBH (DE) | 2015-08-13 | — | — | US | disclosed |
| EP-2890380-A2 | DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | Merck Patent GmbH (DE) | 2015-07-08 | — | — | EP | disclosed |
| WO-2014032755-A2 | DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | MERCK PATENT GMBH (DE) | 2014-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225369-A1 | DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | DDR2, DDR1, DDRGK1 | EPHX2 3657/4885DDR2 1/4885P2RX3 540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.